Terms: = Prostate cancer AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257
1174 results:
1. Circular RNAs in emt-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance.
Ashrafizadeh M; Dai J; Torabian P; Nabavi N; Aref AR; Aljabali AAA; Tambuwala M; Zhu M
Cell Mol Life Sci; 2024 May; 81(1):214. PubMed ID: 38733529
[TBL] [Abstract] [Full Text] [Related]
2. Nanocarrier - Mediated Salinomycin Delivery Induces Apoptosis and Alters emt Phenomenon in prostate Adenocarcinoma.
Kanchan S; Marwaha D; Tomar B; Agrawal S; Mishra S; Kapoor R; Sushma ; Jha G; Sharma D; Bhatta RS; Mishra PR; Rath SK
AAPS PharmSciTech; 2024 May; 25(5):104. PubMed ID: 38724836
[TBL] [Abstract] [Full Text] [Related]
3. Novel role of LLGL2 silencing in autophagy: reversing epithelial-mesenchymal transition in prostate cancer.
Hong GL; Kim KH; Kim YJ; Lee HJ; Cho SP; Han SY; Yang SW; Lee JS; Kang SK; Lim JS; Jung JY
Biol Res; 2024 May; 57(1):25. PubMed ID: 38720397
[TBL] [Abstract] [Full Text] [Related]
4. Differential analysis of histopathological and genetic markers of cancer aggressiveness, and survival difference in EBV-positive and EBV-negative prostate carcinoma.
Ahmed K; Sheikh A; Fatima S; Ghulam T; Haider G; Abbas F; Sarria-Santamera A; Ghias K; Mughal N; Abidi SH
Sci Rep; 2024 May; 14(1):10315. PubMed ID: 38705879
[TBL] [Abstract] [Full Text] [Related]
5. prostate cancer invasion is promoted by the miR-96-5p-induced NDRG1 deficiency through NF-κB regulation.
Soror AA; Eshagh R; Fahim MR; Jamshidian A; Monfared GH
Klin Onkol; 2024; 38(2):95-101. PubMed ID: 38697817
[TBL] [Abstract] [Full Text] [Related]
6. Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors.
Fu XP; Ji CY; Tang WQ; Yu TT; Luo L
Clin Exp Med; 2024 May; 24(1):93. PubMed ID: 38693424
[TBL] [Abstract] [Full Text] [Related]
7. HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis.
Yang L; Ruan Y; Xu H
BMC Cancer; 2024 Apr; 24(1):544. PubMed ID: 38684944
[TBL] [Abstract] [Full Text] [Related]
8. The Suppression of the Epithelial to Mesenchymal Transition in prostate cancer through the Targeting of MYO6 Using MiR-145-5p.
Armstrong L; Willoughby CE; McKenna DJ
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673886
[TBL] [Abstract] [Full Text] [Related]
9. Knockdown of growth differentiation factor-15 restrains prostate cancer through regulating MAPK/ERK signaling pathway.
Yang M; Guo M; Su C; Hao W; Xu Z
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):162-167. PubMed ID: 38650142
[TBL] [Abstract] [Full Text] [Related]
10. Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
Wu C; Zhu H; Zhang Y; Ding L; Wang J
PLoS One; 2024; 19(4):e0290753. PubMed ID: 38598542
[TBL] [Abstract] [Full Text] [Related]
11. Overexpression of REST Represses the Epithelial-Mesenchymal Transition Process and Decreases the Aggressiveness of prostate cancer Cells.
Indo S; Orellana-Serradell O; Torres MJ; Castellón EA; Contreras HR
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542313
[TBL] [Abstract] [Full Text] [Related]
12. Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of Wnt/β-catenin signaling pathway.
Zhang X; Li H; Wang Y; Zhao H; Wang Z; Chan FL
Cell Death Dis; 2024 Mar; 15(3):234. PubMed ID: 38531859
[TBL] [Abstract] [Full Text] [Related]
13. Targeting HOXA11-AS to mitigate prostate cancer via the glycolytic metabolism: In vitro and in vivo.
Zhang J; Li S; Zhang M; Wang Z; Xing Z
J Cell Mol Med; 2024 Apr; 28(8):e18227. PubMed ID: 38520207
[TBL] [Abstract] [Full Text] [Related]
14. Multifaceted impact of adipose conditioned media: Obesity-driven promotion of prostate cancer and cancer stem cell dynamics.
Erdogan S; Serttas R; Dibirdik I; Turkekul K
Cell Biochem Funct; 2024 Mar; 42(2):e3979. PubMed ID: 38481004
[TBL] [Abstract] [Full Text] [Related]
15. Investigation of in-vitro Anti-cancer and Apoptotic Potential of Garlic-Derived Nanovesicles against prostate and Cervical cancer Cell Lines.
Sharma V; Sinha ES; Singh J
Asian Pac J Cancer Prev; 2024 Feb; 25(2):575-585. PubMed ID: 38415544
[TBL] [Abstract] [Full Text] [Related]
16. Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
Ashrafizadeh M; Zhang W; Tian Y; Sethi G; Zhang X; Qiu A
Cancer Metastasis Rev; 2024 Mar; 43(1):229-260. PubMed ID: 38374496
[TBL] [Abstract] [Full Text] [Related]
17. Cationic solid lipid nanoparticles (SLN) complexed with plasmid DNA enhance prostate cancer cells (PC-3) migration.
Garcia-Fossa F; de Jesus MB
Nanotoxicology; 2024 Feb; 18(1):36-54. PubMed ID: 38300021
[TBL] [Abstract] [Full Text] [Related]
18. ZNF692 promotes cell proliferation, invasion and migration of human prostate cancer cells by targeting the emt signaling pathway.
Chen H; Li Y; Wu G; Zeng Q; Huang H; Zhang G
Eur J Med Res; 2024 Jan; 29(1):88. PubMed ID: 38291502
[TBL] [Abstract] [Full Text] [Related]
19. Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions.
Mei S; Alchahin AM; Tsea I; Kfoury Y; Hirz T; Jeffries NE; Zhao T; Xu Y; Zhang H; Sarkar H; Wu S; Subtelny AO; Johnsen JI; Zhang Y; Salari K; Wu CL; Randolph MA; Scadden DT; Dahl DM; Shin J; Kharchenko PV; Saylor PJ; Sykes DB; Baryawno N
Genome Med; 2024 Jan; 16(1):1. PubMed ID: 38281962
[TBL] [Abstract] [Full Text] [Related]
20. Co-expression of Twist and Snai1: predictor of poor prognosis and biomarker of treatment resistance in untreated prostate cancer.
Said R; Hernández-Losa J; Moline T; de Haro RSL; Zouari S; Blel A; Rammeh S; Derouiche A; Ouerhani S
Mol Biol Rep; 2024 Jan; 51(1):226. PubMed ID: 38281235
[TBL] [Abstract] [Full Text] [Related]
[Next]
